Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (opens original article in a new tab)

Jazz Pharmaceuticals and AbCellera have partnered to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors.

• Jazz Pharmaceuticals and AbCellera announced a collaboration to develop T-cell engaging multispecific antibodies.
• The partnership focuses on gastrointestinal cancers and other solid tumors using AbCellera's discovery platform.
• Jazz has exclusive rights to develop and commercialize the programs after paying option fees.